ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Gastrointestinal SPORE To Be Recompeted

June 23, 1995

Research Triangles Lands Plant Drug Contract Renewal

April 9, 1976

NIH Advisors Urge Stronger Peer Review, Clinical Center Renewal

May 20, 1994

Statin Drugs May Prevent Breast Cancer, Lab Suggests

April 25, 2003

Bypass Budget Will Call For 15-percent Increase

February 18, 2011

House-Senate Conference Agrees On $1 Billion For NCI, Increases For All NIH Organizations

August 3, 1979